Novel coronavirus pneumonia patent was issued by the Biden administration in May 5th. US Trade Secretary Katherine Tai announced the US government's decision in a statement on the 5th.

Prior to this, the U.S. pharmaceutical companies had a fierce internal debate on this matter and vigorously fought back. Dai Qi said novel coronavirus pneumonia was ended by the government's efforts to popularize safe and effective vaccines as soon as possible. She also said the U.S. government will continue to strengthen cooperation with the private sector and all possible partners, expand the manufacture and distribution of vaccines, and strive to increase the raw materials needed for the production of these vaccines.

Novel coronavirus pneumonia vaccine is likely to be expanded worldwide and the narrowing of vaccination gap between rich and poor countries is narrowed. Novel coronavirus pneumonia is a part of the global shortage of pneumonia vaccine, but the bigger problem is manufacturing, Ron Klein, Ron, director of the White House Office of the United States, said on 2 th. Klain. He said the White House would release more information "in the next few days.".